PVLA
PALVELLA THERAPEUTICS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 31 ▲ Palvella Therapeutics reported full-year 2025 financial results and…
- Aug 31 FDA: Palvella Therapeutics Completes Rolling Submission of New…
- Sep 11 to Sep 16 ▼ 4 days of insider sells: $3.9M by 2 insiders, avg $151.54
- Sep 18 ▼ Director George M. Jenkins sold a total of ~27,500 shares worth ~$4.…
- Oct 12 to Oct 21 ▼ 4 days of insider sells: $4.1M by 2 insiders, avg $129.41
- Oct 16 William Blair initiates
- Oct 28 FDA: Palvella Announces FDA Acceptance and Priority Review of Q…
- Oct 28 ▲ Palvella Therapeutics announced that the FDA has accepted its NDA fo…
- Oct 28 ▲ Palvella Therapeutics announced FDA acceptance and Priority Review o…
- Nov 5 Palvella reported Q3 2026 net loss of $24.6M ($1.70/share), wider th…
- Nov 5 ▲ Palvella reported Q3 2026 results with a net loss of $24.6M ($1.70/s…
- Nov 10 to Nov 11 ▼ 2 days of insider sells: $2.1M by 1 insider, avg $166.65
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $10.1M.
- InstitutionsBULLISH
Q3 2026: 27 added (2 new), 14 trimmed or exited. Largest new: Westfield Capital Management $54.6M, William Blair Investment Management $26.9M.
- AnalystsBULLISH
22 of 23 rate it Buy or better.
- Short sellersSTEADY
Short interest +8.1% to 2.60M shares. 11.5 days to cover, ≈17.8% of shares.
- TrendUPTREND
1% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| WESTFIELD CAPITAL MANAGEMENT CO LP | NEW | $54.6M |
| MARSHALL WACE, LLP | DOUBLED | $45.5M |
| Invesco Ltd. | DOUBLED | $43.1M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | NEW | $26.9M |
| FMR LLC | TRIM | $17.5M |
| UBS Group AG | ADD | $16.3M |
| Aberdeen Group plc | TRIM | $8.7M |
| Russell Investments Group, Ltd. | DOUBLED | $6.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
23 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only INITIATE | |
| Nov 9, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 6, 2026 | Oppenheimer MAINTAIN | Outperform |
| Oct 28, 2026 | Chardan Capital MAINTAIN | Buy |
| Oct 16, 2026 | William Blair INITIATE | Outperform |
| Oct 12, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Martini Jeffrey S Chief Scientific Officer Nov 11, 2026 | SELL | $243.2K |
Martini Jeffrey S Chief Scientific Officer Nov 11, 2026 | SELL | $188.9K |
Martini Jeffrey S Chief Scientific Officer Nov 11, 2026 | EXERCISE | $61.2K |
Martini Jeffrey S Chief Scientific Officer Nov 11, 2026 | SELL | $101.2K |
Martini Jeffrey S Chief Scientific Officer Nov 11, 2026 | SELL | $34.0K |
Martini Jeffrey S Chief Scientific Officer Nov 11, 2026 | SELL | $270.8K |
Martini Jeffrey S Chief Scientific Officer Nov 11, 2026 | SELL | $201.3K |
Martini Jeffrey S Chief Scientific Officer Nov 10, 2026 | SELL | $33.6K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
26 filings · 10 press releases · 4 bullish · 2 bearish · 1 mixed · 19 neutral- NEUTRAL SC 13G/ANov 16, 2026
Frazier Life Sciences Public Fund, L.P. filed an amendment to its Schedule 13G for Palvella Therapeutics, reporting a 5.9% passive stake as of September 30, 2026, with 848,376 shares. This is a new disclosure from Frazier, which was not previously listed as a filer in the cross-filing context.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 10, 2026
{ "summary": "CEO Jeffrey Martini filed a Form 144 notice of intent to sell 50,000 shares of…
LLM returned non-JSON response. Review the filing manually.
- BULLISH 8-KNov 5, 2026
Palvella reported Q3 2026 results with a net loss of $24.6M ($1.70/share), wider than the $11.3M…
The PDUFA date of February 28, 2027 is the next major catalyst. Monitor for any FDA advisory committee meeting announcements or complete response letter risks. The company's cash position of $236.7M…
- NEUTRAL PRESS-RELEASENov 5, 2026
Palvella reported Q3 2026 net loss of $24.6M ($1.70/share), wider than the $11.3M loss in Q3 2025…
The NDA acceptance with Priority Review is the primary catalyst, with a clear PDUFA date in February 2027. Monitor for any FDA advisory committee meeting announcements and the company's commercial…
All PVLA filing & press-release reports (36)
- SC 13G/A reportNov 16, 2026
- 144 reportNov 10, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 5, 2026
- INST-CLUSTER reportNov 3, 2026
- SC 13G/A reportOct 28, 2026
- PRESS-RELEASE reportOct 28, 2026
- 8-K reportOct 28, 2026
- CLUSTER reportOct 23, 2026
- PRESS-RELEASE reportOct 15, 2026
- 144 reportOct 13, 2026
- CLUSTER reportSep 18, 2026
- 144 reportSep 2, 2026
- INST-CLUSTER reportAug 9, 2026
- 8-K reportAug 4, 2026
- PRESS-RELEASE reportJul 30, 2026
- PRESS-RELEASE reportJul 28, 2026
- 8-K reportJun 30, 2026
- PRESS-RELEASE reportJun 22, 2026
- 8-K reportJun 16, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportMay 15, 2026
- 8-K reportMay 15, 2026
- 8-K reportMay 13, 2026
- 8-K reportMay 7, 2026
- PRESS-RELEASE reportApr 30, 2026
- 8-K reportMar 31, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportMar 31, 2026
- PRESS-RELEASE reportMar 27, 2026
- PRESS-RELEASE reportMar 24, 2026
- PRESS-RELEASE reportMar 23, 2026
- PRESS-RELEASE reportMar 10, 2026
- CLUSTER reportFeb 27, 2026
- PRESS-RELEASE reportMar 2, 2026
- 8-K reportFeb 24, 2026